# BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial, Strengthens IP Portfolio, Reports Q2 2025 Results

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced second-quarter 2025 results and corporate updates. The pivotal Phase 3 trial in early Alzheimer’s disease (NCT06709014) now includes 76 secured U.S. sites, with 46 actively enrolling, 38 patients dosed, and nearly 200 in screening. Enrollment is progressing on schedule with a 50% screen failure rate as expected. Recent milestones include presenting four scientific posters at AAIC 2025, hiring a director of biostatistics, hosting a trial update webcast, and securing global IP coverage for crystal buntanetap. As of June 30, 2025, cash and equivalents totaled $17.1 million, up from $10.6 million at year-end 2024. Quarterly R&D expenses were $5.2 million versus $5.8 million in the prior-year period, while G&A expenses declined to $1.1 million from $2.0 million. Net loss per share narrowed to $0.32 from $0.44.

 To view the full press release, visit https://ibn.fm/iO1TH

 About Annovis Bio Inc.

 Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn , YouTube , and X .

 NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-annovis-bio-inc-nyse-anvs-advances-phase-3-alzheimers-trial-strengthens-ip-portfolio-reports-q2-2025-results/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/annovis-bio-advances-alzheimer-s-treatment-in-phase-3-trial/c1d73648b545580c015186edc61994e4) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1mp62ah/annovis_bio_advances_alzheimers_treatment_in/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/13/milktXOd.webp)